Surgical resection and chemotherapy improve survival rate for patients with hepatoblastoma

2001 ◽  
Vol 36 (5) ◽  
pp. 755-759 ◽  
Author(s):  
Ana Carceller ◽  
Hervé Blanchard ◽  
Josette Champagne ◽  
Dickens St-Vil ◽  
Arié L. Bensoussan
Keyword(s):  
Survival Rate ◽  
Surgical Resection ◽  
Improve Survival Rate

scholarly journals CTNI-63. PROGNOSTIC FACTORS IN PATIENTS WITH BASAL GANGLIA GERM-CELL TUMORS: A RETROSPECTIVE ANALYSIS OF THE SINGLE CHINESE INSTITUTE EXPERIENCE FROM 2009 TO 2019

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii57-ii57
Author(s):  
Qingjun Hu ◽  
Juan Li ◽  
Mingyao Lai ◽  
Cheng Zhou ◽  
Zhaoming Zhou ◽  
...  
Keyword(s):  
Survival Rate ◽  
Basal Ganglia ◽  
Germ Cell ◽  
Retrospective Analysis ◽  
Surgical Resection ◽  
Germ Cell Tumors ◽  
Progression Free Survival ◽  
Course Of Disease ◽  
Free Survival

Abstract OBJECTIVE To evaluate the clinical factors related to the prognosis of basal ganglia germ cell tumors. METHODS A retrospective analysis of 52 cases of the basal ganglia germ cell tumors treated from January 2009 to January 2019 in the department of oncology of Guangdong Sanjiu Brain Hospital. The median age: 12 years (range: 5–32), The median course of disease: 11.7 months (range: 1–54). Thirteen cases were diagnosed by biopsy and 39 cases were diagnosed by elevated tumor markers. There were 31 patients (59.6%) diagnosed with germinomas and 21 patients (40.4%) with non-germ germ cell tumors. Univariate and multivariate survival analysis was performed. RESULTS To October 15, 2019, the median follow-up time was 30.4 months (range 2–124 months). The 5-year survival rate was 85%, and the 5-year progression-free survival rate was 84%. Multivariate analysis found whether serum AFP was greater than 100mIU / ml, (with HR: 11.441,95% CI: 2.09–47.66, P = 0.005),the degree of surgical resection(with HR 5.323 (1.19–23.812), P = 0.029), PD as the effect of radiotherapy (HR: 16.53, (1.19–23.81), P = 0.001) were independent prognostic factor affecting survival. CONCLUSION The pathological type, degree of surgical resection, and response to initial treatment can all affect survival.

scholarly journals Case Report: Carcinoma of Colon

2018 ◽  
Vol 4 (1) ◽  
pp. 1-3
Author(s):  
sushila ladumor ◽  
Adham Darweesh
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Survival Rate ◽  
Gastrointestinal Tract ◽  
Colorectal Carcinoma ◽  
Surgical Resection ◽  
Early Stage ◽  
Occult Lesion ◽  
Carcinoma Of Colon ◽  
Ct And Mri

Colorectal cancer is a disease that is curable if diagnosed at early stage and also it is preventable if predisposing adenomas are detected and removed. Colorectal Carcinoma (CRC) is commonest malignancy of the gastrointestinal tract and is the second most usually diagnosed cancer in adults, mainly at 6th to 7th decades of life[2]. CT and MRI are the modalities of choice used for staging. Colonoscopy for better evaluation and tissue diagnosis as well as to see other occult lesion. Surgical resection may be curative although five-year survival rate is 40 - 50 %.

Enhanced anti-metastatic therapy with down-regulation of heparinase expression by ROS-responsive micellar nanoparticles

Nanoscale ◽  
2021 ◽  
Author(s):  
Yicong Zhang ◽  
Yuai Li ◽  
Shiqi Huang ◽  
Hanming Zhang ◽  
Qing Lin ◽  
...  
Keyword(s):  
Survival Rate ◽  
Cancer Patients ◽  
Malignant Tumor ◽  
Vital Role ◽  
Down Regulation ◽  
Improve Survival Rate ◽  
Micellar Nanoparticles

Metastasis is a major sign of malignant tumor which plays a vital role in cancer-related death. Suppressing metastasis is an important way to improve survival rate of cancer patients. Herein,...

PS02.192: TWO CASES OF PRIMARY MALIGNANT MELANOMA OF ESOPHAGUS TREATED WITH SUBTOTAL ESOPHAGECTOMY

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 176-176
Author(s):  
Ryosuke Hirohata ◽  
Manabu Emi ◽  
Yoichi Hamai ◽  
Yuta Ibuki ◽  
Morihito Okada
Keyword(s):  
Lymph Node ◽  
Survival Rate ◽  
Malignant Melanoma ◽  
Lymph Node Metastasis ◽  
Surgical Resection ◽  
Primary Malignant Melanoma ◽  
Lower Esophagus ◽  
Subtotal Esophagectomy ◽  
Node Metastasis ◽  
Upper Gastrointestinal

Abstract Background Malignant melanoma of the primary esophagus is rare, in general it has high malignancy and poor prognosis. We report two cases of early-stage primary malignant melanoma of esophagus (PMME) underwent subtotal esophagectomy. Methods Case presentation Results [Case 1]A 66-year-old man was pointed out a black legion on the lower esophagus by upper gastrointestinal endoscope for screening purposes. The lesion was diagnosed as malignant melanoma by biopsy. In addition, another black lesion was also found in the pharynx, but there was no malignant cell. Other examinations did not reveal any findings of lymph node metastasis and distant metastasis. We diagnosed PMME (T1aN0M0 Stage 0) and performed surgical resection. Pathologically it was pT1a (LPM), pN0. There is no recurrence, and it is under observation. [Case 2] A 51-year-old woman was conducted upper gastrointestinal endoscopy for the purpose of scarring epigastric pain, and a black lesion was pointed out in lower esophagus. Surgical resection was performed with diagnosis of PMME (T1bN0M0 Stage I). The pathological stage was pT1a (MM), pN0. Conclusion The 5 year survival rate of malignant melanoma of primary esophagus is poor with about 30 to 35%, and especially in cases with lymph node metastasis, the survival rate further decreases. The both cases were discovered accidentally by endoscopic examination, leading to early diagnosis and early treatment. Therefore, long survival is expected. There is also a report that melanosis is associated with melanoma, so case 1 requires careful follow-up observation. Disclosure All authors have declared no conflicts of interest.

Histological features and prognosis of patients with mucoepidermoid carcinoma of the parotid gland

1998 ◽  
Vol 112 (10) ◽  
pp. 944-947 ◽  
Author(s):  
Masashi Suzuki ◽  
Issei Ichimiya ◽  
Futoshi Matsushita ◽  
Goro Mogi
Keyword(s):  
Overall Survival ◽  
Survival Rate ◽  
Parotid Gland ◽  
Surgical Resection ◽  
Mucoepidermoid Carcinoma ◽  
Histological Features ◽  
Lower Survival Rate ◽  
Free Interval ◽  
Her 2 ◽  
Grade 3

AbstractHistological features and prognosis of patients with mucoepidermoid carcinoma of the parotid gland were analysed. Tumours from 13 patients were classified according to histological grades and immunoreactivity for HEK-2/neu. Surgical resection of the tumour was performed for all patients, and the overall five-year survival rate was 69 per cent. The patients whose histological grades were 1 or 2 showed a 100 per cent five-year survival rate, but no patient with grade 3 survived five years. Also, patients who had tumours that overexpressed HER-2/new had a lower survival rate (25 per cent) than patients with tumours that had weaker immunostaining (89 per cent). We considered tumours classified as grade 3 plus strong HER-2/neu expression to be ‘high malignancy’, and compared them with ‘low malignancy’ tumours that were grade 1 or 2 and had weaker HER-2/new staining. Patients with high malignancy tumours had shorter recurrence-free intervals and shorter overall survival than patients with low malignancy tumours. The overall survival period of the low malignancy cases was much longer than the recurrence-free interval; unlike that in the high malignancy tumour patients. These results suggest that the combination of histological grades and expression of HER-2/neu may be a useful predictor of the prognosis for mucoepidermoid carcinomata.

Comparison of long-term outcome between endoscopic submucosal dissection and surgical resection for early gastric cancer.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 144-144
Author(s):  
Boo Gyeong Kim ◽  
Byung-Wook Kim ◽  
Joon Sung Kim ◽  
Sung Min Park ◽  
Keun Joon Lim ◽  
...  
Keyword(s):  
Overall Survival ◽  
Survival Rate ◽  
Surgical Resection ◽  
Disease Free Survival ◽  
Overall Survival Rate ◽  
Free Survival ◽  
Resection Group ◽  
Disease Free

144 Background: The aim of this study is to evaluate the long-term clinical and oncologic outcome of ESD for differentiated EGC of an expanded indication compared to surgical resection. Methods: Retrospective analyses were performed in patients who underwent ESD or surgical resection for EGC of an expanded indication from 2006 and 2008 in Incheon St. Mary’s Hospital, Seoul St. Mary’s Hospital, Yeouido St. Mary’s Hospital, and St. Paul’s Hospital. First arm study was performed according to pre-ESD diagnosis including pathologic diagnosis and endoscopic findings. Second arm study was obtained from post-ESD final pathologic result. All the patients were checked with endoscopy and stomach CT regularly at least 5 years. Clinical outcomes, disease free survival and overall survival were compared between the ESD group and surgical resection group in each arm. Results: In first arm study, 41 patients who received ESD and 106 patients who received surgical resection were enrolled. Metachronous recur was found in 4 patients among ESD group and in 2 patients among surgical resection group during the follow up period. There was no local recurrence in both groups. The disease free survival was not different between the two groups (ESD vs surgical resection; 87.8 vs 95.3%, p=0.291). The 5-year overall survival rate was 100% in both groups. In second arm study, 74 patients who received ESD and 165 patients who received surgical resection were enrolled. Metachronous recur was found in 5 patients among ESD group and in 2 patients among surgical resection group during the follow up period. Local recurrence did not occur in both groups. Surgical resection group was superior to ESD group in disease free survival (97.6% vs 87.6%, p=0.002). The 5-year overall survival rate was 100% in both groups. Conclusions: ESD for EGC might be acceptable considering the overall survival rates. However, intensive surveillance should be performed to find the metachronous recur after ESD.

Does accelerometer feedback on high-quality chest compression improve survival rate? An in-hospital cardiac arrest simulation

2015 ◽  
Vol 33 (8) ◽  
pp. 993-997 ◽  
Author(s):  
Min Hee Jung ◽  
Je Hyeok Oh ◽  
Chan Woong Kim ◽  
Sung Eun Kim ◽  
Dong Hoon Lee ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Survival Rate ◽  
Chest Compression ◽  
High Quality ◽  
Improve Survival Rate ◽  
Hospital Cardiac Arrest

Association of gemcitabine (GEM) efficacy on unresectable invasive pancreatic carcinoma with intraductal papillary mucinous neoplasms.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 478-478
Author(s):  
Yusuke Hashimoto ◽  
Satoshi Shimizu ◽  
Kazuo Watanabe ◽  
Kumiko Umemoto ◽  
Hiroyuki Okuyama ◽  
...  
Keyword(s):  
Survival Rate ◽  
Pancreatic Carcinoma ◽  
Surgical Resection ◽  
Ductal Carcinoma ◽  
Performance Status ◽  
Progression Free Survival ◽  
Pancreatic Ductal Carcinoma ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Ecog Performance Status ◽  
Mucinous Neoplasms

478 Background: Invasive pancreatic carcinoma associated with intraductal papillary mucinous neoplasms (IC-IPMN) has showed more favorable prognosis than invasive pancreatic ductal carcinoma (IPDC) following surgical resection in some studies. IC-IPMN differs from IPDC in clinical manifestation and biology profile and is mostly surgically resectable in initial presentation. Chemotherapeutic effect on unresectable IC-IPMN is not described in the literature yet. Methods: Our pancreatic cancer database was reviewed to identify 43 patients with IC-IPMN between 2006-2013. IC-IPMN was determined with surgical pathology or with radiological diagnosis and biopsy evidence of adenocarcinoma. Of 43 patients, 14 unresectable IC-IPMN patients received GEM as first-line chemotherapy regimen. We investigated GEM efficacy, Overall Survival (OS), Progression Free Survival (PFS) and 1-year survival rate. Results: Characteristic baseline included gender (male: 9, female: 5), age (median: 73 years old), ECOG performance status (0-1, 92%), location (head 7, body/tail 6, diffuse 1), prior surgical resection (8), biliary intervention (5), metastasis (11), CRP (median: 0.15mg/dl, 0.1-1.0), CA19-9 (median: 29U/ml, 8-20820), CEA (median: 3.1ng/ml, 0.1-237). Median OS, PFS and 1-year survival rate were 24.0 months, 8.0 months and 86%. Gemcitabine therapy demonstrated 14% (2/14) response rate and 79% (11/14) disease control rate. Conclusions: UnresectableIC-IPMN indicates favorable survival and fair response to GEM in our study. Limitations are retrospective study at single center and small population due to its disease rarity.

Sign in / Sign up

Export Citation Format

Share Document